If I worked there, I’d call this week “BioCrystmas.” The company’s first-ever drug approval is followed by encouraging data for their broad-spectrum antiviral in Ebola-infected non-human primates, plus an orphan designation for their hereditary angioedema drug.
Source: Technology
Author
Harry Joiner
“… a dominant recruiter in the client-side multichannel ecommerce space …” — SearchEngineWatch.com